Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | RAB9A | P51151 | 2/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | PLK1 | P53350 | 1/20 | 0.56 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.55 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | NAMPT | P43490 | 2/20 | 0.50 |
| ▸ | ESRRG | P62508 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.48 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.48 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17887994 | 0.89 | SMN1; SMN2 (0.77) | SMN1; SMN2RAB9ANPC1LMNANAMPT | |
| SCHEMBL13814872 | 0.87 | PLK1 (0.53) | SMN1; SMN2RAB9ANPC1PLK1TAS1R3 | |
| SCHEMBL13328247 | 0.87 | SMN1; SMN2 (0.65) | SMN1; SMN2RAB9ANPC1LMNANAMPT | |
| SCHEMBL23589794 | 0.83 | NPC1 (0.54) | SMN1; SMN2RAB9ANPC1PLK1TAS1R3 | |
| SCHEMBL14297350 | 0.83 | NPC1 (0.69) | SMN1; SMN2RAB9ANPC1LMNANAMPT | |
| SCHEMBL17301589 | 0.83 | SMN1; SMN2 (0.69) | SMN1; SMN2RAB9ANPC1LMNANAMPT | |
| SCHEMBL10268332 | 0.83 | HPGD (0.64) | SMN1; SMN2RAB9ANPC1PLK1TAS1R3 | |
| SCHEMBL24648929 | 0.83 | SMN1; SMN2 (0.69) | SMN1; SMN2RAB9ANPC1LMNANAMPT | |
| SCHEMBL6570929 | 0.83 | SMN1; SMN2 (0.69) | SMN1; SMN2RAB9ANPC1LMNANAMPT | |
| SCHEMBL19602703 | 0.83 | SMN1; SMN2 (0.60) | SMN1; SMN2RAB9ANPC1LMNANAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200268898-A1 | GLP-1 RECEPTOR LIGAND MOIETY CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | IONIS PHARMACEUTICALS, INC. | 2020-08-27 | — | — | US | disclosed |
| US-7713944-B2 | Oligomers comprising activated disulfides which bind to plasma proteins and their use for delivery to cells | ISIS PHARMACEUTICALS, INC. (US) | 2010-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200268898-A1 | GLP-1 RECEPTOR LIGAND MOIETY CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | GLP1R, GIPR, GRPR | SMN1; SMN2 3594/4885RAB9A 2724/4885NPC1 2667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.